Gene Therapy Development Summit on March 25-27, 2025 in Boston, United States

Welcome to the 8th Gene Therapy Development Summit

Transforming the Future of Gene Therapies for Rare and Common Diseases

With 14 new gene therapy approvals in the last 18 months, billion-dollar collaborations, and the development of treatments for more common conditions, the gene therapy field is rapidly gaining momentum and broadening scope beyond rare diseases. Returning to Boston in March, the 8th Gene Therapy Development Summit, formerly known as the Gene Therapy for Rare Disorders Summit, will unite 200+ gene therapy experts to tackle the field's biggest challenges of achieving genuine scalability and accessibility to meet growing patient demand.

For the first time, this industry-defining meeting will reflect the field's growing focus on developing therapies for common diseases, whilst addressing existing hurdles in rare and ultra-rare disorders. This is your unparalleled opportunity to delve into:

- The latest global regulatory requirements

- Optimizing routes for CNS

- Ocular and inner ear disorders

- Innovations in capsid engineering and dosing strategies

- Increasing volumetric productivity to reduce CoGs

Join your peers to drive gene therapy innovation across translational, clinical, regulatory, and manufacturing tracks. This event is designed to help attendees navigate the entire gene therapy pipeline.

By refining gene delivery platforms, optimizing manufacturing processes, and navigating regulatory pathways, we can revolutionize the future of gene therapies-bringing them to broader patient populations and significantly enhancing clinical outcomes.

URLs:

Tickets: https://go.evvnt.com/2757908-0?pid=10008

Brochure: https://go.evvnt.com/2757908-3?pid=10008

Time: 8:30 AM - 5:15 PM

Prices:

Conference Only- Drug Developer Pricing: USD 2999.00,

Conference + Focus Day- Drug Developer Pricing: USD 4197.00,

Conference + Workshop Day- Drug Developer Pricing: USD 4197.00,

Conference Only- Academic Pricing: USD 2599.00,

Conference + Focus Day- Academic Pricing: USD 3597.00,

Conference + Workshop Day- Academic Pricing: USD 3597.00,

Conference Only- Service Provider Pricing: USD 3699.00,

Conference + Focus Day- Service Provider Pricing: USD 5097.00,

Conference + Workshop Day- Service Provider Pricing: USD 5097.00

Speakers: Amanda Placone, Senior Director External Innovation - Gene Therapy and & Gene Editing, Eli Lilly, Amanda Rohrig, Director, Patient Advocacy, BridgeBio Gene Therapy, Amber Freed, Founder and CEO, SLC6A1 Connect, Anjulika Chawla, Vice President, Medical Affairs, Clinical Lead, bluebird bio, Brian Kevany, Chief Technical Officer and Chief Scientific Officer, Abeona Therapeutics, Costanza Gorini, Senior Researcher, Beacon Research Operations, Beacon, Craig Malzahn, Senior Vice President, Technical Operations, REGENXBIO, Daniel Chung, Chief Medical Officer, SparingVision, Delphine Agathon, Senior Director - Category Clinician, Pfizer, Elizabeth Leshen, Head Of Safety, Efficiency, Gene Therapy and Rare Disease, Novartis, Francesca Cook, Vice President - Global Pricing and Market Access, REGENXBIO, Gail Ryan Director, Pharmaceutical Transformation, Point32Health, Howard Wu, Co-founder and Chief Scientific Officer, Full Circles Therapeutics, Jean-Phillippe Combal, Co-Founder and Chief Executive Officer, Vivet Therapeutics, Jie Li, Director, Vertex Pharmaceuticals, Kathleen Kirby, Chief Operating Officer, Merlin Therapeutics, Kumar Dhanasekharan, Senior Vice President and Head of Technical Operations, Voyager Therapeutics, Lola Fashoyin-Aje, Deputy Division Associate Director, FDA, Lucia Faccio, Partner, Sofinnova Partners, Mara Inniss, Director, Regulated Gene Editing and Gene Therapy Discover, Obsidian Therapeutics, Mark Trusheim, Director - Strategic, Tufts Medical Center, Marriane Lopez, Senior Research Director, Duke University, Maryl Lambros, Bioinformatics Scientist, Avista Therapeutics, Melissa Penn, Director, Patient Engagement, Research and Development, Bayer, Michael Rak, Principal Scientist, Carbon Biosciences, Mike Lehmicke, Senior Vice President for Science and Industry Affairs, Alliance for Regenerative Medicine, Morten Sogaard, President, Gene Therapy Research and Technical Operations, Astellas Innovation Management, Niccolo Bacchi, Chief Executive Officer, Borea Therapeutics, Olivier Danos, Chief Scientific Officer, REGENXBIO, Peter Marks, Director, CBER, FDA, Priya Chockalingam, VP, Head of Clinical Bioanalytics and Translational Sciences, Beam Therapeutics, Rajeev Boregowda, Associate Director, Bioassay and Molecular Analytical Development, Genomic Medicine CMC, Sanofi, Ravi Iyer, Chief Executive Officer, Script Biosciences, Samir Koirala, Senior Director Head of Genetic, Neurodevelopmental and Epilepsy Disorders Research, Biogen, Sebastian Aguirre, Co-Founder, Vice President and Head of Platform Development, Carbon Biosciences, Sitra Tauscher-Wisniewski, Vice President - Clinical Research, Novartis, Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority, Tynan Patrick, Manager, Gene Therapy Purification Operations, Pfizer, Uditha deAlwis, Vice President - Analytical Development and Quality Control, Sarepta, Van Hoang, Head of Analytical and Quality Control, Spark Therapeutics, Vesselin Mitaksov, Associate Research Fellow, Pfizer, Yasuhiro Kishioka, Review Director, PMDA